XERS - Xeris Pharmaceuticals Inc
Xeris Pharmaceuticals Inc Logo

XERS - Xeris Pharmaceuticals Inc

https://www.xerispharma.com
Buy Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-09 (Snapshot)

Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets ready-to-use injectable and infusible drug formulations. The company is headquartered in Chicago, Illinois.

52W High
$8.03
52W Low
$2.51
MA Status:
50D: Above 200D: Above
Beta (~1 neutral, <0.9 lower risk)
0.91
Valuation
Fair
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
20.92
EV/EBITDA (<8 favorable)
198.24
EV/Revenue (<3 favorable)
5.96
P/S (TTM) (<3 favorable)
5.15
P/B (<3 favorable)
3.34
Ownership
Balanced
Source: Overview
Insiders (1–5% typical)
4.05%
Institutions (25–75% balanced)
56.63%
Shares Outstanding
161,480,000
Float
154,228,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
246,025,000
Gross Profit (TTM)
202,328,000
EPS (TTM)
-0.20
Profit Margin (>10% good)
-0.13%
Operating Margin (TTM) (higher better)
0.06%
ROE (TTM) (>15% strong)
-6.17%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
0.49
Momentum
Bearish momentum
Value
0.3616
Previous
0.4212
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025